CU20140095A7 - Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents

Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Info

Publication number
CU20140095A7
CU20140095A7 CUP2014000095A CU20140095A CU20140095A7 CU 20140095 A7 CU20140095 A7 CU 20140095A7 CU P2014000095 A CUP2014000095 A CU P2014000095A CU 20140095 A CU20140095 A CU 20140095A CU 20140095 A7 CU20140095 A7 CU 20140095A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
compositions containing
preparation procedure
phosphate derivatives
new phosphate
Prior art date
Application number
CUP2014000095A
Other languages
English (en)
Other versions
CU24316B1 (es
Inventor
Tiran Arnaud Le
Diguarher Thierry Le
Jerôme-Benoît Starck
Jean-Michel Henlin
Anne-Francoise Guillouzic
Nanteuil Guillaume De
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
I-Jen Chen
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20140095(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CU20140095A7 publication Critical patent/CU20140095A7/es
Publication of CU24316B1 publication Critical patent/CU24316B1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de fórmula(I) Espacio para Fórmula En la que X, Y, A^1, A^2, R^a, R^b, R^c, R^d, R^3, R^4, T y R^5 son tales como se han definido en la descripción. Medicamentos.
CUP2014000095A 2013-07-23 2014-07-23 Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen CU24316B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357259A FR3008979B1 (fr) 2013-07-23 2013-07-23 Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
CU20140095A7 true CU20140095A7 (es) 2016-02-29
CU24316B1 CU24316B1 (es) 2018-02-08

Family

ID=50288170

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000095A CU24316B1 (es) 2013-07-23 2014-07-23 Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen

Country Status (48)

Country Link
US (3) US9115159B2 (es)
EP (1) EP2829545B1 (es)
JP (1) JP5894638B2 (es)
KR (2) KR101713103B1 (es)
CN (1) CN104341451B (es)
AP (1) AP2014007773A0 (es)
AR (1) AR097008A1 (es)
AU (1) AU2014203808B2 (es)
BR (1) BR102014017997B1 (es)
CA (1) CA2856886C (es)
CL (1) CL2014001865A1 (es)
CR (1) CR20140336A (es)
CU (1) CU24316B1 (es)
CY (1) CY1117834T1 (es)
DK (1) DK2829545T3 (es)
DO (1) DOP2014000163A (es)
EA (1) EA027444B1 (es)
EC (1) ECSP14008757A (es)
ES (1) ES2593417T3 (es)
FR (1) FR3008979B1 (es)
GE (1) GEP201706704B (es)
HK (1) HK1204623A1 (es)
HR (1) HRP20161202T8 (es)
HU (1) HUE029616T2 (es)
IL (1) IL233580B (es)
JO (1) JO3160B1 (es)
MA (1) MA37213B1 (es)
MD (1) MD4551C1 (es)
ME (1) ME02641B (es)
MX (1) MX351467B (es)
MY (1) MY173258A (es)
NI (1) NI201400080A (es)
PE (1) PE20150218A1 (es)
PH (1) PH12014000194B1 (es)
PL (1) PL2829545T3 (es)
PT (1) PT2829545T (es)
RS (1) RS55098B1 (es)
RU (1) RU2617682C2 (es)
SA (1) SA114350669B1 (es)
SG (1) SG10201403939WA (es)
SI (1) SI2829545T1 (es)
SV (1) SV2014004771A (es)
TN (1) TN2014000301A1 (es)
TW (1) TWI527824B (es)
UA (1) UA119738C2 (es)
UY (1) UY35661A (es)
WO (1) WO2015011399A1 (es)
ZA (1) ZA201405418B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY37316A (es) * 2016-07-07 2018-01-31 Servier Lab Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
UA125138C2 (uk) * 2016-07-22 2022-01-19 Ле Лаборатуар Сервьє Комбінація інгібітора bcl-2 та інгібітора mcl-1, їхнє застосування і фармацевтичні композиції
AU2017300738A1 (en) * 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
EA039621B1 (ru) * 2017-06-09 2022-02-17 Ле Лаборатуар Сервье Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
AR112440A1 (es) * 2017-07-06 2019-10-30 Servier Lab Forma cristalina de un inhibidor de bcl-2, un proceso para su preparación y composiciones farmacéuticas que la contienen
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412B1 (en) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
CN110606860B (zh) * 2019-09-29 2021-12-10 上海勋和医药科技有限公司 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
JP7773734B2 (ja) * 2021-03-12 2025-11-20 エイル セラピューティクス,インコーポレイテッド Bcl-2阻害剤としてのテトラヒドロインドリジン-1-カルボキサミドを有する化合物
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501514B1 (en) * 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US20050124614A1 (en) * 2002-07-03 2005-06-09 Axys Pharmaceuticals, Inc. 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
AU2006331765A1 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
US7902218B2 (en) * 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
MY162157A (en) * 2007-04-16 2017-05-31 Abbott Lab Substituted indole mcl-1 inhibitors
MX2009012610A (es) 2007-05-22 2009-12-11 Astellas Pharma Inc Compuesto de tetrahidroisoquinolina 1-sustituido.
WO2009102468A1 (en) * 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
WO2010080503A1 (en) * 2008-12-19 2010-07-15 Genentech, Inc. Heterocyclic compounds and methods of use
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120301080A1 (en) 2011-05-23 2012-11-29 Senko Advanced Components, Inc. True one piece housing fiber optic adapter
BR112014015308A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013096051A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CN103177906A (zh) 2011-12-26 2013-06-26 西门子公司 用于中压开关设备的断路器
ITPR20110103A1 (it) 2011-12-27 2013-06-28 G E A F S R L Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza
US9114953B2 (en) 2011-12-29 2015-08-25 Inventio Ag Emergency operation of elevators based on an indicated emergency condition
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE212013000059U1 (de) 2012-01-24 2014-09-11 Danfoss Power Electronics A/S Entfeuchter

Also Published As

Publication number Publication date
DOP2014000163A (es) 2015-01-15
BR102014017997A2 (pt) 2015-11-17
CA2856886A1 (fr) 2015-01-23
BR102014017997B1 (pt) 2020-05-19
PT2829545T (pt) 2016-07-13
FR3008979B1 (fr) 2015-07-24
CA2856886C (fr) 2016-08-02
CN104341451B (zh) 2018-04-03
PH12014000194A1 (en) 2015-06-29
FR3008979A1 (fr) 2015-01-30
RS55098B1 (sr) 2016-12-30
MA37213B1 (fr) 2017-03-31
DK2829545T3 (en) 2016-09-19
CU24316B1 (es) 2018-02-08
EA201400754A2 (ru) 2014-12-30
RU2014130129A (ru) 2016-02-10
EA201400754A3 (ru) 2015-03-31
AR097008A1 (es) 2016-02-10
HK1204623A1 (en) 2015-11-27
MD20140073A2 (en) 2015-01-31
PL2829545T3 (pl) 2016-12-30
RU2617682C2 (ru) 2017-04-26
US20170143746A1 (en) 2017-05-25
EA027444B1 (ru) 2017-07-31
JP2015028017A (ja) 2015-02-12
KR20170001694A (ko) 2017-01-04
TWI527824B (zh) 2016-04-01
PE20150218A1 (es) 2015-02-14
KR101713103B1 (ko) 2017-03-07
AU2014203808B2 (en) 2018-09-20
MD4551C1 (ro) 2018-09-30
CR20140336A (es) 2015-10-07
HK1201536A1 (zh) 2015-09-04
NZ627178A (en) 2016-01-29
ECSP14008757A (es) 2016-01-29
WO2015011399A1 (fr) 2015-01-29
US20150313923A1 (en) 2015-11-05
TW201504254A (zh) 2015-02-01
CN104341451A (zh) 2015-02-11
MD4551B1 (ro) 2018-02-28
CY1117834T1 (el) 2017-05-17
AP2014007773A0 (en) 2014-07-31
SI2829545T1 (sl) 2016-10-28
HRP20161202T1 (hr) 2016-11-04
MX2014008866A (es) 2015-07-21
EP2829545A1 (fr) 2015-01-28
IL233580A0 (en) 2014-11-02
ZA201405418B (en) 2020-02-26
ME02641B (me) 2017-06-20
HRP20161202T8 (hr) 2016-12-30
SG10201403939WA (en) 2015-02-27
NI201400080A (es) 2014-10-24
US9115159B2 (en) 2015-08-25
SV2014004771A (es) 2015-01-28
MA37213A1 (fr) 2016-06-30
JO3160B1 (ar) 2017-09-20
JP5894638B2 (ja) 2016-03-30
HUE029616T2 (en) 2017-03-28
AU2014203808A1 (en) 2015-02-12
MX351467B (es) 2017-10-17
GEP201706704B (en) 2017-07-25
SA114350669B1 (ar) 2016-04-11
UY35661A (es) 2015-02-27
MY173258A (en) 2020-01-09
EP2829545B1 (fr) 2016-06-22
IL233580B (en) 2020-03-31
CL2014001865A1 (es) 2015-06-26
UA119738C2 (uk) 2019-08-12
ES2593417T3 (es) 2016-12-09
TN2014000301A1 (fr) 2015-12-21
PH12014000194B1 (en) 2015-06-29
US9597341B2 (en) 2017-03-21
KR20150011785A (ko) 2015-02-02
US20150031648A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY35467A (es) Compuestos orgánicos
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2017017008A (es) Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CR20160272A (es) REGULADORES DE Nrf2
DOP2018000082A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CR20160031A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2017007377A (es) Compuestos organicos.
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20120109A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35958A (es) Derivados de quinolina como insecticidas y acaricidas
PY1736656A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen